Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EPS (Weighted Average and Diluted) (2023 - 2025)

CG Oncology's EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.51 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 6.25% year-over-year to -$0.51; the TTM value through Dec 2025 reached -$2.07, down 45.77%, while the annual FY2025 figure was -$2.08, 47.52% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.51 in Q4 2025 per CGON's latest filing, up from -$0.57 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.28 in Q2 2024 to a low of -$4.47 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$1.59, with a median of -$0.52 recorded in 2025.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 92.88% in 2024, then plummeted 92.86% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$4.47 in 2023, then soared by 89.26% to -$0.48 in 2024, then fell by 6.25% to -$0.51 in 2025.
  • Per Business Quant, the three most recent readings for CGON's EPS (Weighted Average and Diluted) are -$0.51 (Q4 2025), -$0.57 (Q3 2025), and -$0.54 (Q2 2025).